Conference LibraryGated
J Controlled Release 2026 · DNA-directed multivalent LNP for T cell · Kelly/Kamat
"Lipid nanoparticles (LNPs) are a powerful emerging tool for in vivo T cell engineering to treat diseases ranging from B cell lymphomas and other cancers to autoimmune diseases. Key challenges in designing these therapeutics include achieving both precise cell targeting and effi…
- Type
- paper
- Domain
- oncology
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_verify_wave_3_2026-05-16
- evidence_grade
- A
- category
- lnp_t_cell_targeting_platform
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "preclinical LNP design study · not human clinical · not intended to guide individual patient treatment choices"
- journal
- Journal of Controlled Release
- year
- 2026
- authors
- Mary D Kelly,Neha P Kamat
- abstract_snippet
- "Lipid nanoparticles (LNPs) are a powerful emerging tool for in vivo T cell engineering to treat diseases ranging from B cell lymphomas and other cancers to autoimmune diseases. Key challenges in designing these therapeutics include achieving both precise cell targeting and ef
- pmid
- 41916505
- doi
- 10.1016/j.jconrel.2026.114885
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.